

# Masaru Kanekiyo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/367131/publications.pdf>

Version: 2024-02-01

53  
papers

5,910  
citations

136950

32  
h-index

155660

55  
g-index

65  
all docs

65  
docs citations

65  
times ranked

7300  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial. <i>Nature Medicine</i> , 2022, 28, 383-391.	30.7	65
2	A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination. <i>Nature Medicine</i> , 2022, 28, 373-382.	30.7	16
3	High-Throughput B Cell Epitope Determination by Next-Generation Sequencing. <i>Frontiers in Immunology</i> , 2022, 13, 855772.	4.8	7
4	Structure-based design of stabilized recombinant influenza neuraminidase tetramers. <i>Nature Communications</i> , 2022, 13, 1825.	12.8	21
5	Next-Generation Influenza Vaccines. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a038448.	6.2	23
6	Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	49
7	A comprehensive influenza reporter virus panel for high-throughput deep profiling of neutralizing antibodies. <i>Nature Communications</i> , 2021, 12, 1722.	12.8	41
8	Quadrivalent influenza nanoparticle vaccines induce broad protection. <i>Nature</i> , 2021, 592, 623-628.	27.8	180
9	Sequence-Signature Optimization Enables Improved Identification of Human HV6-1-Derived Class Antibodies That Neutralize Diverse Influenza A Viruses. <i>Frontiers in Immunology</i> , 2021, 12, 662909.	4.8	0
10	An R848-Conjugated Influenza Virus Vaccine Elicits Robust Immunoglobulin G to Hemagglutinin Stem in a Newborn Nonhuman Primate Model. <i>Journal of Infectious Diseases</i> , 2020, 224, 351-359.	4.0	14
11	Glycan repositioning of influenza hemagglutinin stem facilitates the elicitation of protective cross-group antibody responses. <i>Nature Communications</i> , 2020, 11, 791.	12.8	36
12	Influenza-infected newborn and adult monkeys exhibit a strong primary antibody response to hemagglutinin stem. <i>JCI Insight</i> , 2020, 5, .	5.0	13
13	Self-assembling influenza nanoparticle vaccines drive extended germinal center activity and memory B cell maturation. <i>JCI Insight</i> , 2020, 5, .	5.0	64
14	Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens. <i>ELife</i> , 2020, 9, .	6.0	123
15	Activation Dynamics and Immunoglobulin Evolution of Pre-existing and Newly Generated Human Memory B cell Responses to Influenza Hemagglutinin. <i>Immunity</i> , 2019, 51, 398-410.e5.	14.3	107
16	Comparison of adjuvants to optimize influenza neutralizing antibody responses. <i>Vaccine</i> , 2019, 37, 6208-6220.	3.8	16
17	Germline-Encoded Affinity for Cognate Antigen Enables Vaccine Amplification of a Human Broadly Neutralizing Response against Influenza Virus. <i>Immunity</i> , 2019, 51, 735-749.e8.	14.3	71
18	New Vaccine Design and Delivery Technologies. <i>Journal of Infectious Diseases</i> , 2019, 219, S88-S96.	4.0	53

#	ARTICLE	IF	CITATIONS
19	Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages. <i>MBio</i> , 2019, 10, .	4.1	88
20	Epitope-Specific Serological Assays for RSV: Conformation Matters. <i>Vaccines</i> , 2019, 7, 23.	4.4	26
21	A unique nanoparticulate TLR9 agonist enables a HA split vaccine to confer Fc $\gamma$ R-mediated protection against heterologous lethal influenza virus infection. <i>International Immunology</i> , 2019, 31, 81-90.	4.0	12
22	Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells. <i>Immunity</i> , 2019, 50, 1305-1316.e6.	14.3	107
23	Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses. <i>Nature Immunology</i> , 2019, 20, 362-372.	14.5	211
24	High-Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity. <i>Cell</i> , 2019, 179, 1636-1646.e15.	28.9	219
25	Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape. <i>Journal of Virology</i> , 2018, 92, .	3.4	155
26	Two-Component Ferritin Nanoparticles for Multimerization of Diverse Trimeric Antigens. <i>ACS Infectious Diseases</i> , 2018, 4, 788-796.	3.8	65
27	A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. <i>Nature Medicine</i> , 2018, 24, 408-416.	30.7	235
28	Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state. <i>Nature Communications</i> , 2017, 8, 14158.	12.8	58
29	Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after H7N9 immunization in humans. <i>Science Immunology</i> , 2017, 2, .	11.9	84
30	Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein. <i>Nature Communications</i> , 2017, 8, 1877.	12.8	53
31	Virus-Like Particle and Nanoparticle Vaccines. , 2017, , 87-98.		3
32	Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses. <i>Cell</i> , 2016, 166, 609-623.	28.9	270
33	Reconstituted B cell receptor signaling reveals carbohydrate-dependent mode of activation. <i>Scientific Reports</i> , 2016, 6, 36298.	3.3	29
34	Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus. <i>Scientific Reports</i> , 2016, 6, 34108.	3.3	106
35	Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. <i>Science</i> , 2016, 351, 1339-1342.	12.6	370
36	Structural and molecular basis for Ebola virus neutralization by protective human antibodies. <i>Science</i> , 2016, 351, 1343-1346.	12.6	176

#	ARTICLE	IF	CITATIONS
37	In vitro reconstitution of B cell receptor-antigen interactions to evaluate potential vaccine candidates. <i>Nature Protocols</i> , 2016, 11, 193-213.	12.0	51
38	Evaluation of candidate vaccine approaches for MERS-CoV. <i>Nature Communications</i> , 2015, 6, 7712.	12.8	258
39	H5N1 Vaccine-Elicited Memory B Cells Are Genetically Constrained by the IGHV Locus in the Recognition of a Neutralizing Epitope in the Hemagglutinin Stem. <i>Journal of Immunology</i> , 2015, 195, 602-610.	0.8	83
40	Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site. <i>Cell</i> , 2015, 162, 1090-1100.	28.9	278
41	Prefusion-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. <i>Science Translational Medicine</i> , 2015, 7, 309ra162.	12.4	312
42	Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. <i>Nature Medicine</i> , 2015, 21, 1065-1070.	30.7	567
43	Flow Cytometry Reveals that H5N1 Vaccination Elicits Cross-Reactive Stem-Directed Antibodies from Multiple Ig Heavy-Chain Lineages. <i>Journal of Virology</i> , 2014, 88, 4047-4057.	3.4	220
44	Outer Domain of HIV-1 gp120: Antigenic Optimization, Structural Malleability, and Crystal Structure with Antibody VRC-PG04. <i>Journal of Virology</i> , 2013, 87, 2294-2306.	3.4	34
45	Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. <i>Nature</i> , 2013, 499, 102-106.	27.8	682
46	Intradermal Delivery of Recombinant Vaccinia Virus Vector DIs Induces Gut Mucosal Immunity. <i>Scandinavian Journal of Immunology</i> , 2010, 72, 98-105.	2.7	7
47	Delivery of Human Immunodeficiency Virus Vaccine Vectors to the Intestine Induces Enhanced Mucosal Cellular Immunity. <i>Journal of Virology</i> , 2009, 83, 7166-7175.	3.4	23
48	Different Vaccine Vectors Delivering the Same Antigen Elicit CD8+ T Cell Responses with Distinct Clonotype and Epitope Specificity. <i>Journal of Immunology</i> , 2009, 183, 2425-2434.	0.8	27
49	Enhanced Induction of Intestinal Cellular Immunity by Oral Priming with Enteric Adenovirus 41 Vectors. <i>Journal of Virology</i> , 2009, 83, 748-756.	3.4	25
50	A novel CD4-conjugated ultraviolet light-activated photocatalyst inactivates HIV-1 and SIV efficiently. <i>Journal of Medical Virology</i> , 2008, 80, 1322-1331.	5.0	14
51	Mucosal Administration of Completely Non-Replicative Vaccinia Virus Recombinant Dairen I strain Elicits Effective Mucosal and Systemic Immunity. <i>Scandinavian Journal of Immunology</i> , 2008, 68, 476-483.	2.7	3
52	Priming-Boosting Vaccination with Recombinant Mycobacterium bovis Bacillus Calmette-Guèrin and a Nonreplicating Vaccinia Virus Recombinant Leads to Long-Lasting and Effective Immunity. <i>Journal of Virology</i> , 2005, 79, 12871-12879.	3.4	60
53	Mycobacterial Codon Optimization Enhances Antigen Expression and Virus-Specific Immune Responses in Recombinant Mycobacterium bovis Bacille Calmette-Guèrin Expressing Human Immunodeficiency Virus Type 1 Gag. <i>Journal of Virology</i> , 2005, 79, 8716-8723.	3.4	37